-
The new partner will test oral yew alcohol
Time of Update: 2021-02-26
Athenex, Cancer Research UK's Portfolio Alliance and the NIHR Clinical Research Network Industry Alliance have announced a partnership to test chemotherapy drugs that can be oral in early clinical trials.
-
Puma Biotech Licensing Partners are market-licensed by Nerlynx
Time of Update: 2021-02-24
transaminase or glutamate transaminase, nail disease, dry skin, bloating, weight loss and urinary tract infections. The most common adverse reaction to drug suspension was diarrhoea, which we observed in 16.8% of patients treated with nitini. 1.7
-
New results in the journal Science: PD-1 Antibody "New Partner" - iNK Cell Therapy
Time of Update: 2021-02-24
the amplification and performance of iNK cells (Source: TranslationAl Medicine) In mouse models of ovarian cancer allogeneic transplantation, iNK cells exhibited strong anti-tumor function, and the tumor burden was significantly and continuously reduced in mice after treatment.
-
DeGale Wins Partner of the Year 2015
Time of Update: 2021-02-22
reason to believe: the Chamber of Commerce's direct leadership, coordination, supervision, service and escort, with the company's technical strength and production scale, with the support of enterprises, De Jiali will produce more high-quality paint
-
Artificial sweeteners may not be a good partner for diabetics
Time of Update: 2021-02-15
, many people choose to replace sucrose and glucose with artificial sweeteners, whether to control calorie intake or worry about raising blood sugar. But the results of this study may allow people to reassess the effects of artificial
-
Milk powder partner is a solid beverage long-term food harmful to health
Time of Update: 2021-02-05
actual composition is mostly glucose, very easy to produce satiety, affecting the intake of other nutrients, which contains hot de-fire ingredients, mostly cool drugs, easy to hurt the spleen and stomach of infants and young children, resulting
-
PD-1 co-partner CIC:1/3 of non-small cell lung cancer patients reached complete remission
Time of Update: 2021-02-05
options for late-stage NSCLC therapy, thereby improving patient prognostication and quality of life. overall, the combination of CIK cells and PD-1 blocking antibodies has good tolerance and encouraging clinical activity, and it is expected
-
PD-1 antibody "new partner" - ENPP1 inhibitor
Time of Update: 2021-01-24
Source: Pharmaceutical Rubik's Cube Pro Cancer cells have chromosomal instability, and as cancer cells divide, DNA fragments and even entire chromosomes can be repeated, mutated, or completely lost. the more unstable the chromosome, the more
-
CAR-T therapy's new partner, STING astrists
Time of Update: 2021-01-23
Source: Medical Rubik's Cube Pro CAR-T therapies like Novarma's Kymriah and Gilead's Yescarta have changed the fortunes of some leukemia and lymphoma patients, but how to apply this technique to physical tumors is a challenge. Immune pathline
-
New results in the journal Science: PD-1 Antibody "New Partner" - iNK Cell Therapy
Time of Update: 2021-01-21
The amplification and performance of iNK cells (Source: Science Translational Medicine) In mouse models of ovarian cancer allogeneic transplantation, iNK cells exhibited strong anti-tumor function, and after treatment in mice, the tumor burden was significant and decreased continuously.
-
UNITY Anti-Aging Drug Research and Development Made Significant Progress Partner Asasin Pharmaceuticals Received Milestone Payment
Time of Update: 2021-01-15
BM-962 was selected by UNITY as a compound for research and development of UBX1325, and the cooperation was carried out in accordance with the terms of the agreement between the parties.
-
Nature important finding: PD-1 antibody "new partner" - PCSK9 inhibitor
Time of Update: 2021-01-10
cells. the PCSK9 gene also greatly enhances the efficacy of PD-1 antibodies. addition, studies have confirmed that in cancer mouse models, approved PCSK9-listed antibodies and PD-1 antibodies have developed synergies in inhibiting tumor
-
Car-T therapy's new partner, PAK4 inhibitors
Time of Update: 2021-01-03
of the deadliest human malignancies. there are complex immune resistance mechanisms, although traditional treatment can extend the life of GBM patients, but the quality of life of patients after treatment is reduced, survival is often short, so GBM
-
PARP inhibitor "new partner" - CSF-1R inhibitor
Time of Update: 2020-12-23
Inhibition of PARP is not too toxic to healthy cells because there are multiple signaling paths to repair DNA, but for some tumor cells, these tumor cells are particularly sensitive to PARP inhibitors because specific genetic mutations such as BRCA
-
Kang Cai Qinghai Spring plans to buy assets including health food production line RITAMIX partner Ding Production and Sales NMN
Time of Update: 2020-12-12
/> Health Yuan: Received a government subsidy of about 94.44 million yuan on December 8, Health Yuan issued a notice that Health Yuan Pharmaceutical Group Co., Ltd. and its subsidiaries received a total of about 94.44 million yuan in government subsidies
-
"Taste" partners plan to work together to create a new three-dimensional exhibition model
Time of Update: 2020-12-09
to purchase high-quality products, from the source to ensure food safety, while meeting the buyers efforts, money savings, product cost-effective goals to promote the high-quality development of the entire industry. "taste partner program" is now fully
-
Identification of New Interacting Partners for Atypical Rho GTPases: A SILAC-Based Approach
Time of Update: 2020-11-27
In this chapter, we describe how the SILAC technology can be applied to the identification of new interacting partners for atypical – constitutively active – Rho GTPases, i.e. RhoBTB3.
-
Milk powder partner is a "gimmick" do not blindly buy
Time of Update: 2020-11-26
, eating milk powder partners can neither help the baby to catch fire, but may also cause excessive intake of nutrients, parents do not blindly buy.
-
JAHA: Relationship between partner death and risk of ischemic stroke and cerebral hemorrhage
Time of Update: 2020-11-26
researchers used Cox Proportional Risk Regression to estimate the adjusted risk ratio (aHRs) and corresponding 95% CI over a five-year follow-up period.
-
WACKER develops eco-friendly adhesives with partners
Time of Update: 2020-11-24
mastered biotechnology, WACKER has extensive experience in the field of polymer binding agent production, the two sides will be potato processing residue starch as raw materials for the development of environmentally friendly binds, and in DYNAPLAK's
